Anticonvulsive evaluation and histopathological survey of thalidomide synthetic analogs on lithium-pilocarpine-induced status epilepticus in rats.

Arash Amanlou, Faezeh Eslami, Maryam Shayan, Pejman Mortazavi, Ahmad Reza Dehpour
Author Information
  1. Arash Amanlou: Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, I.R. Iran.
  2. Faezeh Eslami: Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran.
  3. Maryam Shayan: Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran.
  4. Pejman Mortazavi: Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, I.R. Iran.
  5. Ahmad Reza Dehpour: Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran.

Abstract

BACKGROUND AND PURPOSE: Status epilepticus is a severe neurological disorder that can be life-threatening. Thalidomide and its analogs have shown promising results to confront pentylenetetrazole-induced seizures. This study aimed to evaluate the potential effects of three synthesized thalidomide derivatives on lithium-pilocarpine-induced status epilepticus.
EXPERIMENTAL APPROACH: To induce status epilepticus, rats received lithium chloride (127 mg/kg, i.p.) and pilocarpine HCl (60 mg/kg, i.p.) 20 h after lithium chloride injection. Thirty min before pilocarpine HCl administration, rats received hyoscine N-butyl bromide (1 mg/kg, i.p.) and concurrently one of the test compounds (5B, 5C, and 5D), diazepam, thalidomide, or vehicle (4% DMSO) to evaluate their anti-epileptic effects. Epileptic seizures scores were assessed through the Racine scale. Twenty-four h after injection of pilocarpine, brain samples were extracted for further histopathological evaluation.
FINDINGS/RESULTS: Results revealed that among tested compounds (5B, 5C, and 5D), only compound 5C (1 mg/kg) exhibited excellent anti-epileptic activity comparable to diazepam (10 mg/kg). Compound 5D (100 mg/kg) only demonstrated comparable anti-epileptic activity to thalidomide (1 mg/kg). Compound 5B did not have any anti-epileptic activity even at the dose of 100 mg/kg. The histopathological survey showed that compound 5C has more neuroprotective effects than diazepam and thalidomide in the cortex of the brain. In the cornu ammonis 1 region, thalidomide had higher protective properties and in the cornu ammonis 3 and dentate gyrus areas, diazepam had higher efficacy to prevent necrosis.
CONCLUSION AND IMPLICATIONS: Compound 5C is a good candidate for further studies regarding its potency, compared to thalidomide and diazepam.

Keywords

References

  1. J Mol Neurosci. 2013 Nov;51(3):950-8 [PMID: 23636891]
  2. Indian J Pharmacol. 2018 Mar-Apr;50(2):84-87 [PMID: 30100656]
  3. Neurotoxicology. 2016 Jan;52:84-8 [PMID: 26562800]
  4. BMJ. 2007 Jun 9;334(7605):1175-6 [PMID: 17556434]
  5. Expert Opin Pharmacother. 2000 May;1(4):849-63 [PMID: 11249521]
  6. Med Chem. 2012 Sep;8(5):953-63 [PMID: 22741781]
  7. Iran Biomed J. 2011;15(1-2):51-8 [PMID: 21725500]
  8. Eur J Pharmacol. 2017 Nov 15;815:454-461 [PMID: 28987270]
  9. Epilepsia. 2000;41 Suppl 2:S23-30 [PMID: 10885737]
  10. Neurosci Lett. 2018 Feb 22;667:84-91 [PMID: 28011391]
  11. Epilepsy Res. 2011 Aug;95(3):263-9 [PMID: 21592729]
  12. J Infect Dis. 1995 Oct;172(4):1137-40 [PMID: 7561198]
  13. Epilepsy Res. 2016 Oct;126:126-33 [PMID: 27490898]
  14. Int J Biochem Cell Biol. 2007;39(7-8):1489-99 [PMID: 17369076]
  15. Nat Methods. 2012 Jun 28;9(7):676-82 [PMID: 22743772]
  16. Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):269-79 [PMID: 4110396]
  17. Eur J Pharmacol. 2009 Oct 1;619(1-3):15-24 [PMID: 19632220]
  18. Epilepsia. 2014 Jan;55(1):17-25 [PMID: 24446952]
  19. BMC Res Notes. 2017 Apr 26;10(1):167 [PMID: 28446201]
  20. Res Pharm Sci. 2019 Dec 11;14(6):534-543 [PMID: 32038733]
  21. J Toxicol Sci. 2018;43(11):671-684 [PMID: 30405000]
  22. Arch Dis Child. 1998 Jul;79(1):73-7 [PMID: 9771258]
  23. Neuroscience. 1984 Jun;12(2):557-67 [PMID: 6462462]
  24. Epilepsy Res. 2020 Aug;164:106362 [PMID: 32447240]
  25. Epilepsy Behav. 2019 Dec;101(Pt B):106275 [PMID: 31171434]
  26. Epilepsy Behav. 2014 May;34:99-104 [PMID: 24735834]
  27. Epilepsy Res. 2010 Dec;92(2-3):253-7 [PMID: 21035311]

Word Cloud

Created with Highcharts 10.0.0mg/kgthalidomideepilepticus5Cdiazepam1anti-epilepticeffectsstatusratsippilocarpine5B5DhistopathologicalactivityCompoundANDStatusThalidomideanalogsseizuresevaluatelithium-pilocarpine-inducedreceivedlithiumchlorideHClhinjectioncompoundsbrainevaluationcompoundcomparable100surveycornuammonishigherBACKGROUNDPURPOSE:severeneurologicaldisordercanlife-threateningshownpromisingresultsconfrontpentylenetetrazole-inducedstudyaimedpotentialthreesynthesizedderivativesEXPERIMENTALAPPROACH:induce1276020ThirtyminadministrationhyoscineN-butylbromideconcurrentlyonetestvehicle4%DMSOEpilepticscoresassessedRacinescaleTwenty-foursamplesextractedFINDINGS/RESULTS:Resultsrevealedamongtestedexhibitedexcellent10demonstratedevendoseshowedneuroprotectivecortexregionprotectiveproperties3dentategyrusareasefficacypreventnecrosisCONCLUSIONIMPLICATIONS:goodcandidatestudiesregardingpotencycomparedAnticonvulsivesyntheticHippocampusHistopathologyN-Phthalimide

Similar Articles

Cited By (3)